Concert Pharmaceuticals (Concert Pharmaceuticals) Long-Term Debt : $0.00 Mil (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Concert Pharmaceuticals Long-Term Debt?

Concert Pharmaceuticals's Long-Term Debt for the quarter that ended in Sep. 2022 was $0.00 Mil.

Concert Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Concert Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concert Pharmaceuticals Long-Term Debt Chart

Concert Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Long-Term Debt

Get a 7-Day Free Trial

Concert Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Concert Pharmaceuticals (NAS:CNCE) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Concert Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Concert Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Concert Pharmaceuticals (Concert Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concert Pharmaceuticals Inc (NAS:CNCE) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421

Website

https://www.concertpharma.com

Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

Executives

James V Cassella	officer: Chief Development Officer	2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Marc A. Becker	officer: CFO, PFO	175 CROSSING BLVD., 4TH FLOOR, FRAMINGHAM MA 01702
Nancy Stuart	officer: Chief Operating Officer	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Jeffrey A Munsie	officer: Chief Legal Officer	CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON MA 02421
Roger D Tung	director, officer: Chief Executive Officer	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Peter Barton Hutt	director
Thomas G Auchincloss	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Richard Aldrich	director	1365 MAIN STREET, WALTHAM MA 02451
Heek Christi Van	director	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jesper Hoeiland	director	C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451
Ronald W Barrett	director	C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Wilfred E Jaeger	director	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511